Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis [1]

AIDS

Volumn 17, Issue 11, 2003, Pages 1709-

  Woolley, Ian ^a   Tapley, Nicole ^a   Korman, Tony M ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR;

ALLERGY; ANXIETY; CROSS REACTION; DRUG ERUPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NEEDLESTICK INJURY; NEPHROLITHIASIS; PRIORITY JOURNAL; PROPHYLAXIS; STEVENS JOHNSON SYNDROME;

ADULT; DRUG HYPERSENSITIVITY; FEMALE; GUIDELINE ADHERENCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LAMIVUDINE; NEEDLESTICK INJURIES; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; ZIDOVUDINE;

EID: 0042628228     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200307250-00021     Document Type: Letter

References (10)

1. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for post exposure prophylaxis. MMWR 1998; 47 (RR-7):1-28.
2. Centers for Disease Control and Prevention. Severe adverse events attributed to nevirapine regimens for post exposure prophylaxis after HIV exposure worldwide, 1997-2000. MMWR 2001; 49:1153-1156.
3. Parkin JM, Murphy M, Anderson J, El-Gadi S, Forster G, Pinching AJ. Tolerability and side-effects of post-exposure prophylaxis for HIV infection. Lancet 2000; 355:722-723.
4. Puro V. Post-exposure prophylaxis for HIV infection. Italian Registry of Post-Exposure Prophylaxis. Lancet 2000; 355:1556-1557.
5. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos J. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS 2002; 16:397-405.
6. Gajweski LK, Grimone AJ, Melbourne KM, Vanscoy GJ. Characterization of rash with indinavir in a national patient cohort. Ann Pharmacother 1999; 33:17-21.
7. Teira R, Zubero Z, Munoz J, Baraia-Etxaburu J, Santamaria JM. Stevens-Johnson syndrome caused by indinavir. Scand J Infect Dis 1998; 30:634-635.
8. Rabaud C, Bevilacqua S, Beguinot I, Dorvaux V, Schuhmacher H, May T, Canton P. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001; 32:1494-1495.
9. Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, Hogg RS. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting. J Acquired Immune Defic Syndr 2002; 29:547-548.
10. Abraham PE, Sorensen SJ, Baker WH, Cushing HE. Nelfinavir desensitization. Ann Pharmacother 2001; 35:553-556.